DATE: 02 December 2014

TO: NDA 205422

FROM: John W. Metcalfe, Ph.D.
Senior Review Microbiologist
CDER/OPS/New Drug Microbiology Staff

THROUGH: Bryan S. Riley, Ph.D.
Team Leader (Acting)
CDER/OPS/New Drug Microbiology Staff

cc: Kofi Ansah
Senior Project Manager
CDER/OND/ODEI/DPP

SUBJECT: Product Quality Microbiology assessment of Microbial Limits for brexpiprazole
[Submission Dates: 11 July 2014 & 14 October 2014]

The Microbial Limits specification for brexpiprazole is acceptable from a Product Quality Microbiology perspective. Therefore, this submission is recommended for approval from the standpoint of product quality microbiology.

Brexipiprazole is a tablet for oral administration.

The drug product is tested for Microbial Limits at release using a method consistent with USP Chapter <61> (Microbiological Examination of Non-sterile Products: Microbial Enumeration Tests) and <62> (Microbiological Examination of Non-sterile Products: Tests for Specified Microorganisms). The Microbial Limits acceptance criteria are consistent with USP Chapter <1111> (Microbiological Examination of Non-sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use).

The Microbial Limits test methods were verified to be appropriate for use with the drug product following procedures consistent with those in USP Chapter <61> and <62>.

The drug product will also be tested for Microbial Limits annually as part of the post-approval stability protocol.
MEMORANDUM

The microbial enumeration tests, limits and methods are provided in table 1.

Table 1. Microbial Enumeration Tests

<table>
<thead>
<tr>
<th>Limits</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microbial Enumeration Tests</td>
<td></td>
</tr>
<tr>
<td>Total Aerobic Microbial Count: ( \leq \frac{b}{(4)} ) CFU/g</td>
<td>USP&lt;61&gt;, Pour plate method</td>
</tr>
<tr>
<td>Total Yeasts and Molds Count: ( \leq \frac{b}{(4)} ) CFU/g</td>
<td></td>
</tr>
<tr>
<td>Specified Organisms E. coli: Absent</td>
<td>USP&lt;62&gt;</td>
</tr>
</tbody>
</table>

ADEQUATE

Reviewer Comments – The microbiological quality of the drug product is controlled via a suitable testing protocol.

END
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN W METCALFE
12/02/2014

BRYAN S RILEY
12/02/2014
I concur.
**PRODUCT QUALITY MICROBIOLOGY NON-Sterile**

**DRUG PRODUCT FILING CHECKLIST**

<table>
<thead>
<tr>
<th>NDA Number: 205422</th>
<th>Applicant: Otsuka Pharmaceutical Co., Ltd.</th>
<th>Letter Date: 11 July 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug Name:</strong> Brexpiprazole</td>
<td><strong>NDA Type:</strong> 505 (b)(1)</td>
<td><strong>Stamp Date:</strong> 11 July 2014</td>
</tr>
<tr>
<td><strong>Dosage Form:</strong> Tablet</td>
<td><strong>Reviewer:</strong> John W. Metcalfe, PhD</td>
<td></td>
</tr>
</tbody>
</table>

The following are necessary to initiate a review of the NDA application:

<table>
<thead>
<tr>
<th>Content Parameter</th>
<th>Yes</th>
<th>No</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Is the product quality microbiology information described in the NDA and organized in a manner to allow substantive review to begin? Is it legible, indexed, and/or paginated adequately?</td>
<td>X</td>
<td></td>
<td>Module 3.2.P.2 &amp; Module 3.2.P.5.2</td>
</tr>
<tr>
<td>2 Has the applicant submitted an overall description of the manufacturing processes and microbiological controls used in the manufacture of the drug product?</td>
<td></td>
<td></td>
<td>There is a manufacturing process description, but no mention of micro controls.</td>
</tr>
<tr>
<td>3 Has the applicant submitted microbiological specifications for the drug product and a description of the test methods?</td>
<td>X</td>
<td></td>
<td>Table 3.2.P.5.1 &amp; Module 3.2.P.5.2</td>
</tr>
<tr>
<td>4 Has the applicant submitted the results of analytical method verification studies?</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>5 Has the applicant submitted preservative effectiveness studies (if applicable)?</td>
<td></td>
<td></td>
<td>Not applicable.</td>
</tr>
<tr>
<td>6 Is this NDA fileable? If not, then describe why.</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional Comments: The drug product specification proposes skip lot testing for microbial enumeration testing. CDER does not allow skip lot testing for microbial enumeration testing. A Microbiological Information Request for the applicant is on page 2 of this review.

---

08 August 2014

John W. Metcalfe, Ph.D.
Senior Microbiology Reviewer, CDER/OPS/NDMS

---

08 August 2014

Bryan S. Riley, Ph.D.
Team Leader (Acting), CDER/OPS/NDMS
Microbiology Information Request to Forward to Applicant

You propose to perform skip lot testing for the Microbial Limits test for drug product release. Skip-lot testing for drug products is not allowed by regulation (21 CFR 211.165 (a) and (b).) If a drug product release specification includes tests and acceptance criteria for a given attribute, then the test must be performed on every batch. However, microbial limits testing may be omitted from the product release specification provided adequate upstream microbiological controls are established and documented. If you wish to omit the microbial limits specification, more information on your process is needed. Address the following points.

1. Identify and justify critical control points in the manufacturing process that could affect microbial load of the drug product.
   a. 
   b. 

2. Describe microbiological monitoring and acceptance criteria for the critical control points that you have identified. Verify the suitability of your testing methods for your drug product. Conformance to the acceptance criteria established for each critical control point should be documented in the batch record in accordance with 21 CFR 211.188.

3. Describe activities taken when microbiological acceptance criteria are not met at control points.

If you choose to omit microbial limits testing for release, then remove the microbial limits tests and acceptance criteria from the drug product release specification. Alternatively, you may retain a microbial limits specification for product release, but testing must be performed on every lot of drug product produced.

Please submit a revised drug product release specification for whichever microbial limits testing alternative that you select.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOHN W METCALFE
08/08/2014

BRYAN S RILEY
08/08/2014
I concur.